Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017; 16: 69-72
Динамика функциональной активности тромбоцитов и гемостатического статуса у ребенка с хронической иммунной тромбоцитопенией на терапии ромиплостимом
https://doi.org/10.24287/1726-1708-2017-16-3-69-72Аннотация
Список литературы
1. van Bladel E.R., Laarhoven A.G., van der Heijden L.B., Heitink-Polle K.M., Porcelijn L., van der Schoot C.E., et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014; 123: 1556-63.
2. Li J., van der Wal D.E., Zhu G., Xu M., Yougbare I., Ma L., et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015; 6: 7737.
3. Frelinger A.L., 3rd, Grace R.F., Gerrits A.J., Berny-Lang M.A., Brown T., Carmichael S.L., et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015; 126: 873-9.
4. Psaila B., Bussel J.B., Linden M.D., Babula B., Li Y., Barnard M.R., et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119: 4066-72.
5. Haselboeck J., Kaider A., Pabinger I., Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109: 676-83.
6. Suntsova E.V., Demina I.M., Ignatova A.A., Ershov N.M., Trubina N.M., Dobrynina J., et al. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol 2017; 105: 841-8.
7. Korkmaz S., Uslu A.U., Aydin B., Dogan O., Sencan M. Pre-treatment and posttreatment changes in platelet indices in patients with immune thrombocytopenia. Saudi Med J 2013; 34: 591-6.
8. Ignatova A.A., Karpova O.V., Trakhtman P.E., Rumiantsev S.A., Panteleev M.A. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang 2016; 110: 244-52.
9. Rodeghiero F., Michel M., Gernsheimer T., Rugged M., Bianchette V., Bussel J.B., et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013; 121: 2596-606.
Pediatric Hematology/Oncology and Immunopathology. 2017; 16: 69-72
Dynamics of platelet functional activity and hemostatic status in a child with chronic immune thrombocytopenia on romiplostim treatment
https://doi.org/10.24287/1726-1708-2017-16-3-69-72Abstract
Immune thrombocytopenia (ITP) is characterized by changes in both quantity and quality of platelets. As a result, severity of bleeding does not always correllate with the degree of thrombocytopenia, The quality of platelets on treatment becomes difficult to evaluate. The most promising method to investigate quality of platelets in ITP is flow cytometry. Here we describe a clinical case of monitoring of a pediatric ITP patient status on romiplostim treatment for 50 weeks using flow cytometry for platelet functional activity control.
References
1. van Bladel E.R., Laarhoven A.G., van der Heijden L.B., Heitink-Polle K.M., Porcelijn L., van der Schoot C.E., et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014; 123: 1556-63.
2. Li J., van der Wal D.E., Zhu G., Xu M., Yougbare I., Ma L., et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015; 6: 7737.
3. Frelinger A.L., 3rd, Grace R.F., Gerrits A.J., Berny-Lang M.A., Brown T., Carmichael S.L., et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015; 126: 873-9.
4. Psaila B., Bussel J.B., Linden M.D., Babula B., Li Y., Barnard M.R., et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119: 4066-72.
5. Haselboeck J., Kaider A., Pabinger I., Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109: 676-83.
6. Suntsova E.V., Demina I.M., Ignatova A.A., Ershov N.M., Trubina N.M., Dobrynina J., et al. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol 2017; 105: 841-8.
7. Korkmaz S., Uslu A.U., Aydin B., Dogan O., Sencan M. Pre-treatment and posttreatment changes in platelet indices in patients with immune thrombocytopenia. Saudi Med J 2013; 34: 591-6.
8. Ignatova A.A., Karpova O.V., Trakhtman P.E., Rumiantsev S.A., Panteleev M.A. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang 2016; 110: 244-52.
9. Rodeghiero F., Michel M., Gernsheimer T., Rugged M., Bianchette V., Bussel J.B., et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013; 121: 2596-606.
